Bridget Bagert, MD
Neurology · New Orleans, LANPI 1174589824
Payments from drug & device makers
Across 514 payments — averaging $2630.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$412K
- Genentech, Inc.$276K
- AbbVie$235K
- Roche Products Limited$135K
- EMD Serono, Inc.$75K
- Biogen$72K
- plus $146K from 7 others
What the payments were for
- Consulting fees$58,06729%
- Speaking & faculty fees$118,20360%
- Travel & lodging$18,1669%
- Food & beverage$3,6472%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 86 | $412,367 |
| Genentech, Inc. | 54 | $275,986 |
| AbbVie | 22 | $234,873 |
| Roche Products Limited | 219 | $135,081 |
| EMD Serono, Inc. | 45 | $75,321 |
| Biogen | 12 | $72,200 |
| Jazz Pharmaceuticals Inc. | 12 | $61,926 |
| TG Therapeutics, Inc. | 43 | $50,371 |
| GW Research Limited | 1 | $14,500 |
| Amgen | 8 | $8,778 |
| Genentech USA, Inc. | 8 | $6,226 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,430 |
| Boston Scientific | 1 | $112 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$71,594
- BRIUMVI$49,845
- UPLIZNA$8,605
- OCREVUS$6,071
- SPECTRA WAVEWRITER$112
How this compares
$1,352,172 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 62 | $562,147 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 41 | $361,968 |
| CopaxoneGlatiramer Acetate | 37 | $222,905 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 18 | $208,970 |
| Avonex (4 Pack)Interferon Beta-1a | 24 | $205,194 |
| Plegridy PenPeginterferon Beta-1a | 12 | $94,792 |
| GlatopaGlatiramer Acetate | 21 | $81,479 |
| Glatiramer Acetate | 28 | $53,519 |
| MyrbetriqMirabegron | 62 | $43,531 |
| Teriflunomide | 41 | $35,142 |
| Dalfampridine ErDalfampridine | 18 | $7,681 |
| Dimethyl Fumarate | 18 | $7,531 |
| FingolimodFingolimod Hcl | 16 | $6,452 |
| Mycophenolate Mofetil | 26 | $4,249 |
| Gabapentin | 177 | $3,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $72,200 | $205,19424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.
Other neurology in New Orleans
- Joseph TarsiaNew Orleans$1.2M
- Angela TraylorNew Orleans$941K
- Brian CopelandNew Orleans$304K
- John EnglandNew Orleans$268K
- Piotr OlejniczakNew Orleans$241K
- Sheryl Martin-SchildNew Orleans$106K
- Aimee AysenneNew Orleans$41K
- Caroline GoldinNew Orleans$38K
- Elizabeth CrabtreeNew Orleans$36K
- Jesus LoveraNew Orleans$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.